Healthcare
Live Price
Offline$0.36
-1.91% today
1Y Change
-90.89%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Beyond Air, Inc. (XAIR) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.36 and down 90.9% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +219.7%, EPS growth of +62.1%, a dividend yield of 0.0%. What stands out right now is revenue +219.7%, EPS +62.1%, free cash flow +28.6% with operating margin -419.5% and ROIC -90.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines XAIR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XAIR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XAIR Max Drawdown
-91.77%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XAIR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$873.0K
FY Net Income
-$22.9M
+47.0% YoY
Free Cash Flow
-$20.5M
+16.3% YoY
Revenue Growth
+219.7%
EPS Growth
+62.1%
Gross Margin
1.8%
Net Margin
-447.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4M | 1M | 0 | 0 | 873K |
| Gross Profit | -2M | -1M | -555K | 0 | 873K |
| Operating Income | -45M | -63M | -52M | -41M | -22M |
| EBITDA | -42M | -59M | -58M | -43M | -22M |
| Net Income | -47M | -60M | -56M | -43M | -23M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 11M | 29M | 80M | 35M |
| Total Assets | 30M | 57M | 69M | 99M | 41M |
| Total Liabilities | 16M | 30M | 27M | 21M | 10M |
| Shareholder Equity | 14M | 25M | 38M | 73M | 30M |
| Total Debt | 12M | 18M | 4M | 3M | 7M |
| Net Debt | 7M | 6M | -26M | -77M | -28M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
20M
+15.1% YoY
Capital Expenditures
890K
+35.5% YoY
Free Cash Flow
21M
+16.3% YoY
Key ratios
Gross Margin
1.8%
Operating Margin
-419.5%
Net Margin
-447.7%
ROE
-279.6%
Debt / Equity
3.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.